MétaCan
Menu
Back to cohort

Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children’s Oncology Group.

2014· article· en· W2601691317 on OpenAlexaff
Richard Aplenc, Brian T. Fisher, Yimei Li, Todd A. Alonzo, Robert B. Gerbing, Matt Hall, Staci D. Arnold, Yuan‐Shung Huang, Alix E. Seif, Rochelle Bagatell, Lillian Sung, Peter C. Adamson, Alan S. Gamis, Ron Keren

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical studies and practices
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsMedicineProtocol (science)CogRandomized controlled trialClinical trialPopulationInternal medicinePediatricsAlternative medicine

Abstract

fetched live from OpenAlex

7086 Background: NCI-funded cooperative group oncology group trials report clinical outcomes but do not report cost estimates. The Children’s Oncology Group trial AAML0531 randomized 1,022 de novo AML patients to standard chemotherapy ± gemtuzumab (GMTZ). As previously reported, GMTZ improved event-free survival but did not improve overall survival. The Pediatric Health Information Systems (PHIS) database contains standardized inpatient cost data (SC) on children treated at 43 freestanding pediatric hospitals in the United States. We hypothesized that SC would be similar for both treatment arms during on-protocol therapy but lower in the GMTZ arm during all follow up time (defined as time from on-protocol to last COG follow-up). Methods: Data from AAML0531 and PHIS were probabilistically merged. PHIS SC were defined by hospital costs multiplied by the ratio of cost to charges and adjusted by consumer price index and geographical region. All available SC were extracted for all merged patients and compared with bivariate statistics. Results: Merged patients (n = 373) were representative of the overall trial population. Follow-up time was marginally longer in the GMTZ arm, 223 days vs 238 days, p = 0.1. The overall median SC was $309,785 ($1,943/day) on-protocol and $467,767 ($1,707/day) for all follow-up time. The per day SC did not differ by study arm on-protocol but per day SC were significantly higher in the non-GTMZ arm, $1,877/day vs $1,648/day over all follow-up time, p = 0.03. Table 1 summarizes departmental SC; Room and Board (RB) comprises approximately 50-60% of all SC. Conclusions: Merging of PHIS data with COG data enables estimation of regimen specific SC. GMTZ does not increase SC during protocol therapy but is associated with lower per day SC over all follow-up time. Further work is needed to increase the number of patients with SC data, to examine SC variability, and define drivers of SC. Clinical trial information: NCT00372593. Department Median on protocol Percent* Median overall Percent* Pharmacy 60,866 19.6% 99,881 21% Supplies 3,419 1.1% 5,101 1.1% Laboratory 34,460 11.1% 54,786 11.7% Radiology 4,523 1.5% 7,146 1.5% Clinical 8,282 2.7% 19,142 4% RB 181,774 58.7% 241,794 52% *Percentage of overall median SC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.019
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.015
Threshold uncertainty score0.080

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0150.019
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.004
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.161
GPT teacher head0.507
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicPharmaceutical studies and practicesFrench-language works237,207